Elizabeth J. Phillips, MD, FRCPC, FRACP, FIDSA, FAAAAI

Professor of Medicine, Pharmacology, and Pathology, Microbiology, and
Immunology, Vanderbilt University Medical Center
Director of Personalized Immunology, John A. Oates Chair in Clinical Research Professor and Director, Centre for Clinical Pharmacology and infectious Diseases
Institute for Immunology and Infectious Diseases, Murdoch University, Australia


Elizabeth Phillips, MD, is Professor of Medicine and Pharmacology and is co-appointed as Director of Personalized Immunology at the Oates Institute for Experimental Therapeutics at Vanderbilt University Medical Center and as Director of the Centre for Clinical Pharmacology and Infectious Diseases at the Institute for Immunology and Infectious Diseases, Murdoch University in Perth, Western Australia. She is also co-director for the personalized-care scientific working group for the Vanderbilt Center for AIDS Research. She has been immensely successful in answering important scientific questions about variation in drug responses, particularly interactions between drugs and the immune system. She played a key leadership role in establishing HLA-B*57:01 and the roadmap from discovery to translation of HLA-B*57:01 as a routine screening marker used prior to abacavir prescription to prevent hypersensitivity. Her current work focuses on defining genetic, molecular, and cellular signatures in severe cutaneous adverse drug reactions such as SJS/TEN that will guide prevention and management. She is currently part of the PGRN and a principal investigator on a P50 grant to study the immunopathogenesis and improvement in the prediction of HLA-mediated drug reactions (


CarletonBruce Headshot.jpgBruce Carleton, BSc, PharmD

Professor of Pediatrics & Chair, Division of Translational Therapeutics
Faculty of Medicine, University of British Columbia (UBC)
Director, Pharmaceutical Outcomes Programme, BC Children’s Hospital (BCCH)
Senior Clinician Scientist, BC Children’s Hospital Research Institute


Bruce Carleton, BSc, PharmD, is Professor of Pediatrics and Chair, Division of Translational Therapeutics, Department of Pediatrics at the University of British Columbia (UBC), Vancouver, BC, Canada. Dr. Carleton is a Senior Clinician Scientist at the British Columbia Children’s Hospital Research Institute. He directs the Pharmaceutical Outcomes Programme at BC Children’s Hospital, and he has served in this capacity since 1994. He holds additional academic appointments at UBC in the Centre for Health Services and Policy Research, the School of Population and Public Health, and the Faculty of Pharmaceutical Sciences. He is also Adjunct Professor in the School of Health Information Science, University of Victoria. Dr. Carleton’s public service is expansive. It includes serving as a charter member of the national Canadian Drug Expert Committee  Dr. Carleton also serves the US Government as a Special Government Employee to advise the Advisory Committee for Pharmaceuticals and Clinical Pharmacology of the FDA. 



Wen-Hung Chung, MD, PhD

Professor and Director of Department of Dermatology,
Chang Gung Memorial Hospital, Linkou and Taipei Branch, Taiwan
Director of Drug Hypersensitivity Clinical and Research,
Chang Gung Memorial Hospital, Taiwan
Director of Whole-Genome Research Core Laboratory of Human Diseases,
Chang Gung Memorial Hospital, Taiwan
Associate Professor, School of Medicine,
Chang Gung University, Taoyuan, Taiwan


Wen-Hung Chung, MD, PhD, serves as a physician of dermatology and a specialist in the field of severe cutaneous adverse drug reactions (SCARs) and cutaneous immunologic disorders. He is a director of the Department of Dermatology and Drug Hypersensitivity Clinical and Research Center at Taipei and Linkou Chang Gung Memorial Hospital. Dr. Chung has dedicated himself to the investigation of SCARs for over a decade, and his devotion and findings have had a great impact in clinic. Dr. Chung and his team have identified genetics and biomarkers of SCARs. He defined strong genetic associations of HLA-B*15:02 with carbamazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and HLA-B*58:01 with allopurinol-SCARs. In addition, he discovered granulysin as the major mediator for the extensive keratinocyte death in SJS or TEN. These remarkable breakthroughs have been published in Nature and Nature Medicine in 2004 and 2008, respectively. Currently, these markers have been clinically applied as the risk predictors before the prescription of carbamazepine or allopurinol to prevent the development of SCARs in many countries. These contributions have earned Dr. Chung several awards, including the 2009 47th Ten Outstanding Young Persons in Taiwan and the 2011 International League of Dermatological Societies (ILDS) Young Dermatologist International Achievement Award.